Collplant Biotechnologies Other Operating Expenses Over Time
| CLGN Stock | USD 4.23 0.04 0.95% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Collplant Biotechnologies Performance and Collplant Biotechnologies Correlation. Collplant |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Collplant Biotechnologies. If investors know Collplant will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Collplant Biotechnologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.53) | Revenue Per Share 0.06 | Quarterly Revenue Growth (0.98) | Return On Assets (0.34) | Return On Equity (0.62) |
The market value of Collplant Biotechnologies is measured differently than its book value, which is the value of Collplant that is recorded on the company's balance sheet. Investors also form their own opinion of Collplant Biotechnologies' value that differs from its market value or its book value, called intrinsic value, which is Collplant Biotechnologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Collplant Biotechnologies' market value can be influenced by many factors that don't directly affect Collplant Biotechnologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Collplant Biotechnologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Collplant Biotechnologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Collplant Biotechnologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Other Operating Expenses Analysis
Compare Collplant Biotechnologies and related stocks such as Keros Therapeutics, Merus BV, and Vericel Corp Ord Other Operating Expenses Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| KROS | 11.3 M | 11.3 M | 11.3 M | 11.3 M | 11.3 M | 11.3 M | 11.3 M | 11.3 M | 11.3 M | 20 M | 44.2 M | 76.5 M | 107.7 M | 170.1 M | 178.6 M |
| MRUS | 13.9 M | 13.9 M | 13.9 M | 13.9 M | 22.1 M | 26.6 M | 32 M | 67.2 M | 80.4 M | 89.8 M | 105.8 M | 139.1 M | 201.6 M | 200.5 M | 210.5 M |
| VCEL | 12.1 M | 29.1 M | 33.8 M | 21 M | 52.3 M | 67.8 M | 71 M | 78.9 M | 94.8 M | 129.1 M | 121.8 M | 164 M | 181.4 M | 204 M | 214.2 M |
| IPSC | 20 M | 20 M | 20 M | 20 M | 20 M | 20 M | 20 M | 20 M | 20 M | 20 M | 49.2 M | 94.9 M | 139 M | 148.8 M | 99.4 M |
| STTK | 28.6 M | 28.6 M | 28.6 M | 28.6 M | 28.6 M | 28.6 M | 28.6 M | 28.6 M | 28.6 M | 35 M | 46.9 M | 75.3 M | 104 M | 93.6 M | 70.3 M |
| CCCC | 35.8 M | 35.8 M | 35.8 M | 35.8 M | 35.8 M | 35.8 M | 35.8 M | 35.8 M | 35.8 M | 56.8 M | 93.6 M | 127.9 M | 160.6 M | 159.8 M | 116.3 M |
| PRLD | 15 M | 15 M | 15 M | 15 M | 15 M | 15 M | 15 M | 15 M | 15 M | 28.1 M | 58.8 M | 113.7 M | 123.5 M | 132.3 M | 86.4 M |
| GLUE | 8 M | 8 M | 8 M | 8 M | 8 M | 8 M | 8 M | 8 M | 8 M | 8 M | 28 M | 72.9 M | 112.4 M | 143.3 M | 80.2 M |
| MOLN | 25.3 M | 25.3 M | 25.3 M | 25.3 M | 24.8 M | 31.3 M | 42.5 M | 45.9 M | 47.8 M | 57 M | 67.7 M | 72.7 M | 72.9 M | 68.1 M | 55.6 M |
| MNOV | 2 M | 16.1 M | 11.7 M | 10 M | 9.2 M | 8.8 M | 10.9 M | 13 M | 15.6 M | 14 M | 14.2 M | 14.3 M | 14.6 M | 10.9 M | 14.5 M |
| ANEB | 173.4 K | 173.4 K | 173.4 K | 173.4 K | 173.4 K | 173.4 K | 173.4 K | 173.4 K | 173.4 K | 173.4 K | 3.6 M | 6.8 M | 11.8 M | 8.3 M | 6.8 M |
| CSBR | 2.1 M | 16.2 M | 14.6 M | 17.8 M | 22.1 M | 21.5 M | 22.2 M | 21.6 M | 26.8 M | 33.6 M | 40.7 M | 48.5 M | 58.3 M | 57.5 M | 60.4 M |
| REPL | 8.2 M | 8.2 M | 8.2 M | 8.2 M | 8.2 M | 8.2 M | 8.2 M | 17 M | 28.4 M | 53.1 M | 77.1 M | 115.1 M | 174.2 M | 234.8 M | 246.5 M |
| CRNX | 6 M | 6 M | 6 M | 6 M | 6 M | 6 M | 6 M | 9.1 M | 28.7 M | 53.8 M | 75 M | 108.8 M | 172.6 M | 226.6 M | 238 M |
| NAMS | 5.4 M | 5.4 M | 5.4 M | 5.4 M | 5.4 M | 5.4 M | 5.4 M | 5.4 M | 5.4 M | 5.4 M | 5.4 M | 36.4 M | 116.8 M | 183.2 M | 94 M |
| PRTC | 14 M | 14 M | 14 M | 10.1 M | 19.5 M | 55.4 M | 78.4 M | 116.1 M | 120.4 M | 144.1 M | 127.9 M | 160.3 M | 199.9 M | 149.5 M | 109.6 M |
| IKNA | 32.2 M | 32.2 M | 32.2 M | 32.2 M | 32.2 M | 32.2 M | 32.2 M | 32.2 M | 32.2 M | 32.2 M | 53.7 M | 65.1 M | 86.5 M | 84.6 M | 70.9 M |
| HCWB | 7.4 M | 7.4 M | 7.4 M | 7.4 M | 7.4 M | 7.4 M | 7.4 M | 7.4 M | 7.4 M | 7.4 M | 9.9 M | 13.4 M | 21.8 M | 28.6 M | 17.8 M |
| XCUR | 12.2 M | 12.2 M | 12.2 M | 12.2 M | 12.2 M | 12.2 M | 17.2 M | 20.1 M | 21.9 M | 27.9 M | 42 M | 62.1 M | 30.7 M | 15 M | 14.2 M |
Collplant Biotechnologies and related stocks such as Keros Therapeutics, Merus BV, and Vericel Corp Ord Other Operating Expenses description
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Collplant Biotechnologies. It is also known as Collplant Biotechnologies overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.My Equities
My Current Equities and Potential Positions
| Collplant Biotechnologies | CLGN |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Israel |
| Exchange | NASDAQ Exchange |
USD 4.23
Check out Collplant Biotechnologies Performance and Collplant Biotechnologies Correlation. To learn how to invest in Collplant Stock, please use our How to Invest in Collplant Biotechnologies guide.You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Collplant Biotechnologies technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.